#### 

## **SEE THE PURIGEN ADVANTAGE**

## **Proof-of-Performance (POP) Study**

Purigen is transforming nucleic acid purification using isotachophoresis (ITP) which separates and focuses charged molecules in solution based solely on their ionic mobility. The Purigen system doesn't use harsh denaturing and dehydrating steps that damage nucleic acids, and it also doesn't include any washing steps. The result is higher nucleic acid yields with no contamination and increased quality. Amplifiable yields versus conventional column-based techniques are typically 2–10x higher for FFPE samples and 1.1–1.5x for cells.

- Higher amplifiable yields
- Higher quality and longer fragment lengths
- Simplified workflows which save time while minimizing the risk of sample contamination
- Cost per 8 samples = \$200

### How a POP Study Works

- Select a sample type to submit. Currently supported sample types are cultured cells, sorted cells or FFPE.
- 2 Determine how many samples you want to submit. Samples are processed in batches of 8.
- 3 Discuss the goals of your POP with you local Regional Account Manager who will generate a Proof-of-Performance Request Form.
- **4** Fill out a sample manifest and send your samples to Purigen.
- 5 Receive your purified DNA in approximately 10 business days.

#### **Purigen FFPE Workflow**

#### Hands-on time is less than 3 minutes per sample.

PURIGE

RIOSYST



#### For more information, contact us at info@purigenbio.com.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

© 2019 Purigen Biosystems Inc. All rights reserved.

# Proof-of-Performance (POP) **REQUEST FORM**



info@purigenbio.com

#### GENERAL INFORMATION

Institute / Company	Institute	/ Company	
---------------------	-----------	-----------	--

**Request Date** 

Project Requestor Email

**Project Requestor** 

**Desired Project Completion Date** 

**Project Requestor Phone** 

#### PROJECT INFORMATION

What is the main reason for your interest in Purigen's Proof-of-Performance program and what specific pain points in your current workflow are you trying to address?

Please provide a brief description of the project.

What downstream analysis will be performed after nucleic acid purification?

#### SAMPLE INFORMATION

Please provide a brief description of the samples.

Have aliquots/portions of the samples that you plan to submit for the POP been purified using an alternative nucleic acid purification technology?

YES	<b>If so,</b> were any issues encountered when purifying the samples (please describe)? Can you share any QC data?
NO	<b>If not,</b> do you plan to purify aliquots/ portions of the samples using an alternative nucleic acid purification technology so that you can compare results?

Is the downstream assay sensitive to the purification volume? Please note that cell samples will be eluted into 45-65 uls and FFPE samples into 40 uls.

Number of Samples

	Cells	6			🖉 FFPE				
Cell ty	/pe				Sample format		Scrolls / Curls		Mounted slides
Estimated cell count				Thickness and surface area					
					Tissue type				
Re	comme	ended cell preparatio	n prior to ship	oping:					
1.	Spin t line-s	the cells/media solution pecific spin speed).	for 5 min at 50	D x g (or a given cell	BIOCK age (if known)				
2.	Caref	ully remove the media w	ithout disturbin	g the pellet.	We recomme	and chi	nning FEDE cor	nnine at	+ 1_9°C
З.	Add 1	75 µL 1X PBS (without M	gCl <sub>2</sub> or CaCl <sub>2</sub> ) to	the pellet.	werecomme	iiu aiii	рршу ггес заг	прісэ а	14-00
4.	Spin t speci	the cells/PBS for 5 min a fic spin speed).	at 500 x g (or a g	given cell line-	PLEASE NOTE				
5.	Caref	ully remove all the PBS v	without disturbi	ng the pellet. It	1. We cannot a	ccept sa	amples that are c	ontamina	ated or otherwise contain
	is imp	portant that the majority	of the 1X PBS is	removed (~ 5	materials tha	at are ac	tively infectious t	o humar	15.
	aspira	ated).	e supernatant i	Scompletely	<b>2.</b> Please indica	ate if any	y samples contair	n any bra	in or spinal tissue.
6.	Flash	freeze the pellet and sh	ip the pellet on	dry ice.	<b>3.</b> Please indica	ate any s	special handling c	ondition	S.
	DEFIN	NITION OF PROGE	RAM SUCCI	ESS					
What	criteria	will be used to detern	nine whether o	r not this POP is suc	cessful?				
If the I	POP is (	deemed successful wi	nat else would	be needed to suppor	t the purchase of a Pu	urigen s	system?		
Do you have budget to support an instrument purchase at this time?			What is your timeline to purchase?						
Can co	ompara	itive purification or do	wnstream ana	lysis data be shared	with Purigen:				
$\bigcirc$	YES		<b>lf yes,</b> what o you plan to g	comparative data do enerate?					
		~							
<b>Can P</b> (detail	<b>urigen</b> ( Is of spe	<b>use any comparison d</b> acific usage will be shar	<b>ata for market</b> ed before public	ing purposes cation):	YES		) ND		
	APPR	OVAL							
Regio	nal Acc	ount Manager		Customer			SVP of Sales /	Marketi	ng



PURIGE

BIOSYSTEMS